Fanconi anemia: Difference between revisions

(Created page with "Fanconi anemia (FA) is the most common inherited bone marrow failure syndrome, characterized by progressive '''pancytopenia''', congenital anomalies, and markedly increased cancer susceptibility. Emergency physicians encounter FA patients presenting with '''hemorrhagic emergencies''', '''febrile neutropenia''', '''severe anemia''', and '''malignancy complications'''. Critically, FA patients have '''extreme sensitivity to DNA-damag...")
 
(Moved intro paragraph into Background as bullets; removed excessive bold from bullet lead-ins; added Anemia DDX and Increased bleeding DDX templates; bold retained for critical items only)
Line 1: Line 1:
Fanconi anemia (FA) is the most common inherited bone marrow failure syndrome, characterized by progressive '''[[Pancytopenia|pancytopenia]]''', congenital anomalies, and markedly increased cancer susceptibility. Emergency physicians encounter FA patients presenting with '''hemorrhagic emergencies''', '''[[Febrile neutropenia|febrile neutropenia]]''', '''severe anemia''', and '''malignancy complications'''. Critically, FA patients have '''extreme sensitivity to DNA-damaging agents''' — standard-dose chemotherapy and radiation can cause fatal toxicity if FA is undiagnosed.<ref name="StatPearls">Fanconi Anemia. ''StatPearls''. 2024. PMID: 32119428</ref> '''Not''' the same as [[Fanconi syndrome]] (a renal tubular disorder).
==Background==
==Background==
*Fanconi anemia (FA) is the most common inherited bone marrow failure syndrome, characterized by progressive [[Pancytopenia|pancytopenia]], congenital anomalies, and markedly increased cancer susceptibility.
*Emergency physicians encounter FA patients presenting with hemorrhagic emergencies, [[Febrile neutropenia|febrile neutropenia]], severe anemia, and malignancy complications.
*Critically, FA patients have extreme sensitivity to DNA-damaging agents — standard-dose chemotherapy and radiation can cause fatal toxicity if FA is undiagnosed.<ref name="StatPearls">Fanconi Anemia. ''StatPearls''. 2024. PMID: 32119428</ref> Not the same as [[Fanconi syndrome]] (a renal tubular disorder).
*Autosomal recessive (most common) or X-linked recessive genetic disorder affecting DNA interstrand crosslink (ICL) repair<ref name="StatPearls"/>
*Autosomal recessive (most common) or X-linked recessive genetic disorder affecting DNA interstrand crosslink (ICL) repair<ref name="StatPearls"/>
*Mutations in '''at least 22 FA genes''' (FANCA most common, ~65% of cases)
*Mutations in '''at least 22 FA genes''' (FANCA most common, ~65% of cases)
Line 7: Line 8:
*Higher carrier frequency in Ashkenazi Jewish, Afrikaner, and Spanish Romani populations
*Higher carrier frequency in Ashkenazi Jewish, Afrikaner, and Spanish Romani populations
*Median age of diagnosis: 6-8 years; '''~25% of patients have NO congenital anomalies''' and may not be diagnosed until adulthood<ref name="Medscape">Fanconi Anemia. ''Medscape''. 2024.</ref>
*Median age of diagnosis: 6-8 years; '''~25% of patients have NO congenital anomalies''' and may not be diagnosed until adulthood<ref name="Medscape">Fanconi Anemia. ''Medscape''. 2024.</ref>
*'''90% develop bone marrow failure by age 40'''<ref name="GeneReviews"/>
* 90% develop bone marrow failure by age 40<ref name="GeneReviews"/>
*Median mortality age ~20 years (improving with modern transplant techniques)
*Median mortality age ~20 years (improving with modern transplant techniques)
*Leading causes of death: bone marrow failure > malignancy (AML/MDS, head/neck squamous cell carcinoma) > complications of transplant
*Leading causes of death: bone marrow failure > malignancy (AML/MDS, head/neck squamous cell carcinoma) > complications of transplant
Line 19: Line 20:
*Mucocutaneous bleeding, petechiae, purpura, ecchymoses
*Mucocutaneous bleeding, petechiae, purpura, ecchymoses
*GI hemorrhage
*GI hemorrhage
*'''Intracranial hemorrhage''' (particularly dangerous; high-impact activities should be avoided in thrombocytopenic patients)<ref name="FanconiGuidelines">Fanconi Anemia: Guidelines for Diagnosis and Management. 4th ed. Fanconi Anemia Research Fund.</ref>
* Intracranial hemorrhage (particularly dangerous; high-impact activities should be avoided in thrombocytopenic patients)<ref name="FanconiGuidelines">Fanconi Anemia: Guidelines for Diagnosis and Management. 4th ed. Fanconi Anemia Research Fund.</ref>
*Menorrhagia in adolescent/adult females
*Menorrhagia in adolescent/adult females
*Prolonged bleeding from wounds, dental procedures, or minor trauma
*Prolonged bleeding from wounds, dental procedures, or minor trauma


====Infectious emergencies====
====Infectious emergencies====
*'''[[Febrile neutropenia]]''' — the most dangerous acute presentation; treat as per standard [[Febrile neutropenia|febrile neutropenia]] protocols
* [[Febrile neutropenia]] — the most dangerous acute presentation; treat as per standard [[Febrile neutropenia|febrile neutropenia]] protocols
*Recurrent bacterial infections (pneumonia, skin infections, sinusitis, UTIs)
*Recurrent bacterial infections (pneumonia, skin infections, sinusitis, UTIs)
*Oral candidiasis, fungal infections (in severe neutropenia)
*Oral candidiasis, fungal infections (in severe neutropenia)
Line 37: Line 38:
===Congenital anomalies (present in ~75%)===
===Congenital anomalies (present in ~75%)===
*Useful for recognizing the '''undiagnosed''' FA patient presenting to the ED:
*Useful for recognizing the '''undiagnosed''' FA patient presenting to the ED:
*'''Skeletal:''' absent or hypoplastic thumbs, absent/hypoplastic radii (always with thumb abnormalities), short stature, vertebral anomalies
* Skeletal: absent or hypoplastic thumbs, absent/hypoplastic radii (always with thumb abnormalities), short stature, vertebral anomalies
*'''Skin:''' café au lait spots (>50%), diffuse hyperpigmentation, hypopigmented patches
* Skin: café au lait spots (>50%), diffuse hyperpigmentation, hypopigmented patches
*'''Head:''' microcephaly (25%)
* Head: microcephaly (25%)
*'''Eyes:''' microphthalmia, strabismus, epicanthal folds
* Eyes: microphthalmia, strabismus, epicanthal folds
*'''Ears:''' hearing loss (usually conductive), low-set or malformed ears
* Ears: hearing loss (usually conductive), low-set or malformed ears
*'''Renal:''' structural anomalies (horseshoe kidney, ectopic kidney, absent kidney) — 20%<ref name="GeneReviews"/>
* Renal: structural anomalies (horseshoe kidney, ectopic kidney, absent kidney) — 20%<ref name="GeneReviews"/>
*'''Cardiac:''' congenital heart defects — 5%
* Cardiac: congenital heart defects — 5%
*'''GI:''' tracheoesophageal fistula, esophageal/duodenal atresia, imperforate anus
* GI: tracheoesophageal fistula, esophageal/duodenal atresia, imperforate anus
*'''Genitourinary:''' cryptorchidism, hypospadias, micropenis (males); structural uterine/vaginal anomalies (females)
* Genitourinary: cryptorchidism, hypospadias, micropenis (males); structural uterine/vaginal anomalies (females)
*'''VACTERL-H phenotype''' (vertebral, anal, cardiac, tracheoesophageal, renal, limb + hydrocephalus) found in ~12%<ref name="GeneReviews"/>
* VACTERL-H phenotype (vertebral, anal, cardiac, tracheoesophageal, renal, limb + hydrocephalus) found in ~12%<ref name="GeneReviews"/>
*'''25% of FA patients have NO physical anomalies''' — suspect FA in any young patient with unexplained pancytopenia
* 25% of FA patients have NO physical anomalies — suspect FA in any young patient with unexplained pancytopenia


===Malignancy===
===Malignancy===
*'''AML/MDS:''' ~30% lifetime risk; may be the initial presentation of previously undiagnosed FA
* AML/MDS: ~30% lifetime risk; may be the initial presentation of previously undiagnosed FA
*'''Head and neck squamous cell carcinoma:''' greatly increased risk, particularly after stem cell transplant and in patients with graft-versus-host disease
* Head and neck squamous cell carcinoma: greatly increased risk, particularly after stem cell transplant and in patients with graft-versus-host disease
*'''Gynecologic malignancy:''' vulvar and cervical SCC
* Gynecologic malignancy: vulvar and cervical SCC
*'''Liver tumors:''' hepatocellular carcinoma, hepatic adenomas (particularly in patients treated with androgens)
* Liver tumors: hepatocellular carcinoma, hepatic adenomas (particularly in patients treated with androgens)
*'''Critical EM pitfall:''' if an FA patient presents with leukemia or a solid tumor and is given '''standard-dose chemotherapy or radiation''', '''extreme and potentially fatal myelosuppression''' will result due to impaired DNA repair<ref name="StatPearls"/>
* Critical EM pitfall: if an FA patient presents with leukemia or a solid tumor and is given '''standard-dose chemotherapy or radiation''', '''extreme and potentially fatal myelosuppression''' will result due to impaired DNA repair<ref name="StatPearls"/>


==Differential diagnosis==
==Differential diagnosis==
Line 71: Line 72:
*Drug-induced myelosuppression
*Drug-induced myelosuppression
*Systemic lupus erythematosus
*Systemic lupus erythematosus
{{Anemia DDX}}
{{Increased bleeding DDX}}


==Evaluation==
==Evaluation==
===EM workup (acute presentations)===
===EM workup (acute presentations)===
*'''CBC with differential and peripheral smear:'''
* CBC with differential and peripheral smear:
**'''Macrocytosis''' (elevated MCV — often the earliest hematologic abnormality; precedes cytopenias)<ref name="GeneReviews"/>
** Macrocytosis (elevated MCV — often the earliest hematologic abnormality; precedes cytopenias)<ref name="GeneReviews"/>
**Elevated fetal hemoglobin (HbF)
**Elevated fetal hemoglobin (HbF)
**Thrombocytopenia (usually appears first)
**Thrombocytopenia (usually appears first)
Line 81: Line 86:
**Anemia (develops later)
**Anemia (develops later)
**Smear: macrocytes, occasional target cells; blast cells if AML transformation
**Smear: macrocytes, occasional target cells; blast cells if AML transformation
*'''Reticulocyte count:''' low (hypoproliferative anemia)
* Reticulocyte count: low (hypoproliferative anemia)
*'''Type and screen''' — anticipate transfusion needs
* Type and screen — anticipate transfusion needs
*'''BMP:''' electrolytes, renal function (structural renal anomalies are common)
* BMP: electrolytes, renal function (structural renal anomalies are common)
*'''LFTs:''' hepatic adenomas and iron overload from chronic transfusion
* LFTs: hepatic adenomas and iron overload from chronic transfusion
*'''Coagulation studies:''' if active bleeding
* Coagulation studies: if active bleeding
*'''Blood cultures''' (at least 2 sets from separate sites) — before antibiotics if '''febrile neutropenia'''
* Blood cultures (at least 2 sets from separate sites) — before antibiotics if '''febrile neutropenia'''
*'''Urinalysis, chest radiograph''' — as indicated by clinical presentation
* Urinalysis, chest radiograph — as indicated by clinical presentation
*'''Lactate, procalcitonin''' — if sepsis suspected
* Lactate, procalcitonin — if sepsis suspected
*'''ECG''' — if congenital heart disease or cardiomyopathy suspected
* ECG — if congenital heart disease or cardiomyopathy suspected


===When to suspect undiagnosed FA in the ED===
===When to suspect undiagnosed FA in the ED===
Line 95: Line 100:
*Patient with '''unexpected severe toxicity''' from standard-dose chemotherapy or radiation
*Patient with '''unexpected severe toxicity''' from standard-dose chemotherapy or radiation
*Early-onset malignancy (AML in a child/young adult; head/neck SCC in a young non-smoker)
*Early-onset malignancy (AML in a child/young adult; head/neck SCC in a young non-smoker)
*'''Diagnosis is confirmed by chromosomal breakage (fragility) test''' using diepoxybutane (DEB) or mitomycin C — this is not an ED test but should be arranged via hematology consultation<ref name="StatPearls"/>
* Diagnosis is confirmed by chromosomal breakage (fragility) test using diepoxybutane (DEB) or mitomycin C — this is not an ED test but should be arranged via hematology consultation<ref name="StatPearls"/>


==Management==
==Management==
===Hemorrhagic emergencies===
===Hemorrhagic emergencies===
*'''Platelet transfusion:'''
* Platelet transfusion:
**'''Use single-donor platelets''' (reduces alloimmunization risk)<ref name="Medscape"/>
** Use single-donor platelets (reduces alloimmunization risk)<ref name="Medscape"/>
**'''Leukodepleted''' (CMV risk reduction)
** Leukodepleted (CMV risk reduction)
**'''Irradiated''' (prevents transfusion-associated graft-versus-host disease)
** Irradiated (prevents transfusion-associated graft-versus-host disease)
**'''Do NOT use blood products from family members''' — may sensitize the patient and compromise future stem cell transplantation<ref name="FanconiGuidelines"/>
**'''Do NOT use blood products from family members''' — may sensitize the patient and compromise future stem cell transplantation<ref name="FanconiGuidelines"/>
**Transfuse for active bleeding or platelets <10,000/μL (or <50,000/μL if surgery/invasive procedure planned)
**Transfuse for active bleeding or platelets <10,000/μL (or <50,000/μL if surgery/invasive procedure planned)
*'''Avoid:'''
* Avoid:
**NSAIDs and aspirin (impair platelet function)
**NSAIDs and aspirin (impair platelet function)
**IM injections (hematoma risk)
**IM injections (hematoma risk)
**Rectal thermometers, suppositories, enemas (mucosal trauma)
**Rectal thermometers, suppositories, enemas (mucosal trauma)
*'''Epistaxis:''' topical hemostatic agents, anterior packing; avoid posterior packing if possible due to mucosal fragility
* Epistaxis: topical hemostatic agents, anterior packing; avoid posterior packing if possible due to mucosal fragility
*'''Aminocaproic acid (Amicar)''' or '''tranexamic acid''': may be used as adjunctive antifibrinolytic therapy for mucosal bleeding<ref name="FanconiGuidelines"/>
* Aminocaproic acid (Amicar) or '''tranexamic acid''': may be used as adjunctive antifibrinolytic therapy for mucosal bleeding<ref name="FanconiGuidelines"/>


===Febrile neutropenia===
===Febrile neutropenia===
*Manage per standard '''[[Febrile neutropenia]]''' protocols — this is a medical emergency
*Manage per standard '''[[Febrile neutropenia]]''' protocols — this is a medical emergency
*Fever (≥38.3°C single or ≥38.0°C sustained) + ANC <500/μL (or expected to fall below 500/μL)
*Fever (≥38.3°C single or ≥38.0°C sustained) + ANC <500/μL (or expected to fall below 500/μL)
*'''Empiric broad-spectrum antibiotics within 1 hour''' of presentation (e.g., cefepime, piperacillin-tazobactam, or meropenem per institutional protocol)
* Empiric broad-spectrum antibiotics within 1 hour of presentation (e.g., cefepime, piperacillin-tazobactam, or meropenem per institutional protocol)
*Blood cultures before antibiotics (do not delay antibiotics for cultures if not immediately obtainable)
*Blood cultures before antibiotics (do not delay antibiotics for cultures if not immediately obtainable)
*Low threshold for antifungal coverage if not responding to antibiotics within 48-72 hours
*Low threshold for antifungal coverage if not responding to antibiotics within 48-72 hours
*'''G-CSF''' (filgrastim) may be used for neutropenia-related infectious complications with ANC <500/μL<ref name="FanconiGuidelines"/>
* G-CSF (filgrastim) may be used for neutropenia-related infectious complications with ANC <500/μL<ref name="FanconiGuidelines"/>


===Anemia===
===Anemia===
*'''Packed RBC transfusion:'''
* Packed RBC transfusion:
**'''Leukodepleted, irradiated''' (same principles as platelets)<ref name="Medscape"/>
** Leukodepleted, irradiated (same principles as platelets)<ref name="Medscape"/>
**'''Do NOT use family member donors'''
**'''Do NOT use family member donors'''
**Transfusion threshold depends on clinical context; generally for hemoglobin <7 g/dL or symptomatic anemia
**Transfusion threshold depends on clinical context; generally for hemoglobin <7 g/dL or symptomatic anemia
*'''Monitor for transfusional iron overload''' in chronically transfused patients — serum ferritin, cardiac and hepatic MRI T2*
* Monitor for transfusional iron overload in chronically transfused patients — serum ferritin, cardiac and hepatic MRI T2*


===Airway considerations===
===Airway considerations===
*'''Skeletal anomalies''' (vertebral, mandibular) may make intubation difficult<ref name="Anesthesia">Anesthetic Management of a Patient With Fanconi Anemia. ''Anesth Prog''. 2019;66(4):214-217. doi:10.2344/anpr-D-18-00057</ref>
* Skeletal anomalies (vertebral, mandibular) may make intubation difficult<ref name="Anesthesia">Anesthetic Management of a Patient With Fanconi Anemia. ''Anesth Prog''. 2019;66(4):214-217. doi:10.2344/anpr-D-18-00057</ref>
*Short stature may require smaller-than-expected equipment
*Short stature may require smaller-than-expected equipment
*'''Avoid nasal intubation''' if thrombocytopenic (nasal bleeding risk)
* Avoid nasal intubation if thrombocytopenic (nasal bleeding risk)
*Avoid nitrous oxide (suppresses bone marrow via impaired methionine synthetase)<ref name="Anesthesia"/>
*Avoid nitrous oxide (suppresses bone marrow via impaired methionine synthetase)<ref name="Anesthesia"/>


===Medication safety===
===Medication safety===
*'''Avoid NSAIDs and aspirin'''
* Avoid NSAIDs and aspirin
*'''Avoid IM injections'''
* Avoid IM injections
*FA patients receiving '''androgens''' (oxymetholone, danazol) for bone marrow stimulation may have: hepatic dysfunction (peliosis hepatis, adenomas), virilization, lipid abnormalities — consider when interpreting labs
*FA patients receiving '''androgens''' (oxymetholone, danazol) for bone marrow stimulation may have: hepatic dysfunction (peliosis hepatis, adenomas), virilization, lipid abnormalities — consider when interpreting labs
*If cancer is diagnosed or suspected, '''do NOT initiate standard-dose chemotherapy or radiation in the ED''' — consult hematology/oncology experienced in FA management; profoundly reduced doses are required<ref name="StatPearls"/>
*If cancer is diagnosed or suspected, '''do NOT initiate standard-dose chemotherapy or radiation in the ED''' — consult hematology/oncology experienced in FA management; profoundly reduced doses are required<ref name="StatPearls"/>


==Disposition==
==Disposition==
*'''Febrile neutropenia:''' admit; ICU if hemodynamically unstable or severely septic
* Febrile neutropenia: admit; ICU if hemodynamically unstable or severely septic
*'''Active hemorrhage with severe thrombocytopenia:''' admit to monitored setting; hematology consultation
* Active hemorrhage with severe thrombocytopenia: admit to monitored setting; hematology consultation
*'''Severe anemia (Hb <7 g/dL) or symptomatic:''' admit for transfusion and evaluation
* Severe anemia (Hb <7 g/dL) or symptomatic: admit for transfusion and evaluation
*'''New pancytopenia of unknown cause:''' admit or arrange urgent hematology follow-up; do not discharge without a plan for workup
* New pancytopenia of unknown cause: admit or arrange urgent hematology follow-up; do not discharge without a plan for workup
*'''Stable known FA patient with mild cytopenias:''' may discharge with close hematology follow-up and clear return precautions for fever, bleeding, syncope, or worsening weakness
* Stable known FA patient with mild cytopenias: may discharge with close hematology follow-up and clear return precautions for fever, bleeding, syncope, or worsening weakness
*'''All FA patients:''' ensure hematology is involved in care and aware of the ED visit
* All FA patients: ensure hematology is involved in care and aware of the ED visit
*Educate patients/families:
*Educate patients/families:
**Return immediately for '''any''' fever (even low-grade if neutropenic)
**Return immediately for '''any''' fever (even low-grade if neutropenic)

Revision as of 14:26, 19 March 2026

Background

  • Fanconi anemia (FA) is the most common inherited bone marrow failure syndrome, characterized by progressive pancytopenia, congenital anomalies, and markedly increased cancer susceptibility.
  • Emergency physicians encounter FA patients presenting with hemorrhagic emergencies, febrile neutropenia, severe anemia, and malignancy complications.
  • Critically, FA patients have extreme sensitivity to DNA-damaging agents — standard-dose chemotherapy and radiation can cause fatal toxicity if FA is undiagnosed.[1] Not the same as Fanconi syndrome (a renal tubular disorder).
  • Autosomal recessive (most common) or X-linked recessive genetic disorder affecting DNA interstrand crosslink (ICL) repair[1]
  • Mutations in at least 22 FA genes (FANCA most common, ~65% of cases)
  • Prevalence approximately 1:350,000 births; carrier frequency ~1:300 in European/US populations[2]
  • Higher carrier frequency in Ashkenazi Jewish, Afrikaner, and Spanish Romani populations
  • Median age of diagnosis: 6-8 years; ~25% of patients have NO congenital anomalies and may not be diagnosed until adulthood[3]
  • 90% develop bone marrow failure by age 40[2]
  • Median mortality age ~20 years (improving with modern transplant techniques)
  • Leading causes of death: bone marrow failure > malignancy (AML/MDS, head/neck squamous cell carcinoma) > complications of transplant

Clinical features

What the EM physician will see

  • FA patients most commonly present to the ED with complications of pancytopenia:

Hemorrhagic emergencies

  • Epistaxis (often recurrent and severe)
  • Mucocutaneous bleeding, petechiae, purpura, ecchymoses
  • GI hemorrhage
  • Intracranial hemorrhage (particularly dangerous; high-impact activities should be avoided in thrombocytopenic patients)[4]
  • Menorrhagia in adolescent/adult females
  • Prolonged bleeding from wounds, dental procedures, or minor trauma

Infectious emergencies

  • Febrile neutropenia — the most dangerous acute presentation; treat as per standard febrile neutropenia protocols
  • Recurrent bacterial infections (pneumonia, skin infections, sinusitis, UTIs)
  • Oral candidiasis, fungal infections (in severe neutropenia)
  • Sepsis

Anemia-related symptoms

  • Fatigue, weakness, dyspnea on exertion
  • Dizziness, syncope, tachycardia
  • Pallor
  • High-output cardiac failure (rare, with very severe chronic anemia)

Congenital anomalies (present in ~75%)

  • Useful for recognizing the undiagnosed FA patient presenting to the ED:
  • Skeletal: absent or hypoplastic thumbs, absent/hypoplastic radii (always with thumb abnormalities), short stature, vertebral anomalies
  • Skin: café au lait spots (>50%), diffuse hyperpigmentation, hypopigmented patches
  • Head: microcephaly (25%)
  • Eyes: microphthalmia, strabismus, epicanthal folds
  • Ears: hearing loss (usually conductive), low-set or malformed ears
  • Renal: structural anomalies (horseshoe kidney, ectopic kidney, absent kidney) — 20%[2]
  • Cardiac: congenital heart defects — 5%
  • GI: tracheoesophageal fistula, esophageal/duodenal atresia, imperforate anus
  • Genitourinary: cryptorchidism, hypospadias, micropenis (males); structural uterine/vaginal anomalies (females)
  • VACTERL-H phenotype (vertebral, anal, cardiac, tracheoesophageal, renal, limb + hydrocephalus) found in ~12%[2]
  • 25% of FA patients have NO physical anomalies — suspect FA in any young patient with unexplained pancytopenia

Malignancy

  • AML/MDS: ~30% lifetime risk; may be the initial presentation of previously undiagnosed FA
  • Head and neck squamous cell carcinoma: greatly increased risk, particularly after stem cell transplant and in patients with graft-versus-host disease
  • Gynecologic malignancy: vulvar and cervical SCC
  • Liver tumors: hepatocellular carcinoma, hepatic adenomas (particularly in patients treated with androgens)
  • Critical EM pitfall: if an FA patient presents with leukemia or a solid tumor and is given standard-dose chemotherapy or radiation, extreme and potentially fatal myelosuppression will result due to impaired DNA repair[1]

Differential diagnosis

Other inherited bone marrow failure syndromes

  • Dyskeratosis congenita
  • Diamond-Blackfan anemia
  • Shwachman-Diamond syndrome
  • Thrombocytopenia-absent radius (TAR) syndrome

Other causes of pancytopenia

  • Aplastic anemia (acquired)
  • Myelodysplastic syndrome
  • Acute leukemia
  • Megaloblastic anemia (B12/folate deficiency)
  • HIV
  • Drug-induced myelosuppression
  • Systemic lupus erythematosus



Anemia

RBC Loss

RBC consumption (Destruction/hemolytic)


Impaired Production (Hypochromic/microcytic)

  • Iron deficiency
  • Anemia of chronic disease
  • Thalassemia
  • Sideroblastic anemia

Aplastic/myelodysplastic (normocytic)

  • Marrow failure
  • Chemicals (e.g. ETOH)
  • Radiation
  • Infection (HIV, parvo)


Megaloblastic (macrocytic)

Coagulopathy

Platelet Related

Factor Related

Evaluation

EM workup (acute presentations)

  • CBC with differential and peripheral smear:
    • Macrocytosis (elevated MCV — often the earliest hematologic abnormality; precedes cytopenias)[2]
    • Elevated fetal hemoglobin (HbF)
    • Thrombocytopenia (usually appears first)
    • Leukopenia/neutropenia
    • Anemia (develops later)
    • Smear: macrocytes, occasional target cells; blast cells if AML transformation
  • Reticulocyte count: low (hypoproliferative anemia)
  • Type and screen — anticipate transfusion needs
  • BMP: electrolytes, renal function (structural renal anomalies are common)
  • LFTs: hepatic adenomas and iron overload from chronic transfusion
  • Coagulation studies: if active bleeding
  • Blood cultures (at least 2 sets from separate sites) — before antibiotics if febrile neutropenia
  • Urinalysis, chest radiograph — as indicated by clinical presentation
  • Lactate, procalcitonin — if sepsis suspected
  • ECG — if congenital heart disease or cardiomyopathy suspected

When to suspect undiagnosed FA in the ED

  • Young patient with unexplained pancytopenia + macrocytosis ± congenital anomalies
  • Patient with unexpected severe toxicity from standard-dose chemotherapy or radiation
  • Early-onset malignancy (AML in a child/young adult; head/neck SCC in a young non-smoker)
  • Diagnosis is confirmed by chromosomal breakage (fragility) test using diepoxybutane (DEB) or mitomycin C — this is not an ED test but should be arranged via hematology consultation[1]

Management

Hemorrhagic emergencies

  • Platelet transfusion:
    • Use single-donor platelets (reduces alloimmunization risk)[3]
    • Leukodepleted (CMV risk reduction)
    • Irradiated (prevents transfusion-associated graft-versus-host disease)
    • Do NOT use blood products from family members — may sensitize the patient and compromise future stem cell transplantation[4]
    • Transfuse for active bleeding or platelets <10,000/μL (or <50,000/μL if surgery/invasive procedure planned)
  • Avoid:
    • NSAIDs and aspirin (impair platelet function)
    • IM injections (hematoma risk)
    • Rectal thermometers, suppositories, enemas (mucosal trauma)
  • Epistaxis: topical hemostatic agents, anterior packing; avoid posterior packing if possible due to mucosal fragility
  • Aminocaproic acid (Amicar) or tranexamic acid: may be used as adjunctive antifibrinolytic therapy for mucosal bleeding[4]

Febrile neutropenia

  • Manage per standard Febrile neutropenia protocols — this is a medical emergency
  • Fever (≥38.3°C single or ≥38.0°C sustained) + ANC <500/μL (or expected to fall below 500/μL)
  • Empiric broad-spectrum antibiotics within 1 hour of presentation (e.g., cefepime, piperacillin-tazobactam, or meropenem per institutional protocol)
  • Blood cultures before antibiotics (do not delay antibiotics for cultures if not immediately obtainable)
  • Low threshold for antifungal coverage if not responding to antibiotics within 48-72 hours
  • G-CSF (filgrastim) may be used for neutropenia-related infectious complications with ANC <500/μL[4]

Anemia

  • Packed RBC transfusion:
    • Leukodepleted, irradiated (same principles as platelets)[3]
    • Do NOT use family member donors
    • Transfusion threshold depends on clinical context; generally for hemoglobin <7 g/dL or symptomatic anemia
  • Monitor for transfusional iron overload in chronically transfused patients — serum ferritin, cardiac and hepatic MRI T2*

Airway considerations

  • Skeletal anomalies (vertebral, mandibular) may make intubation difficult[5]
  • Short stature may require smaller-than-expected equipment
  • Avoid nasal intubation if thrombocytopenic (nasal bleeding risk)
  • Avoid nitrous oxide (suppresses bone marrow via impaired methionine synthetase)[5]

Medication safety

  • Avoid NSAIDs and aspirin
  • Avoid IM injections
  • FA patients receiving androgens (oxymetholone, danazol) for bone marrow stimulation may have: hepatic dysfunction (peliosis hepatis, adenomas), virilization, lipid abnormalities — consider when interpreting labs
  • If cancer is diagnosed or suspected, do NOT initiate standard-dose chemotherapy or radiation in the ED — consult hematology/oncology experienced in FA management; profoundly reduced doses are required[1]

Disposition

  • Febrile neutropenia: admit; ICU if hemodynamically unstable or severely septic
  • Active hemorrhage with severe thrombocytopenia: admit to monitored setting; hematology consultation
  • Severe anemia (Hb <7 g/dL) or symptomatic: admit for transfusion and evaluation
  • New pancytopenia of unknown cause: admit or arrange urgent hematology follow-up; do not discharge without a plan for workup
  • Stable known FA patient with mild cytopenias: may discharge with close hematology follow-up and clear return precautions for fever, bleeding, syncope, or worsening weakness
  • All FA patients: ensure hematology is involved in care and aware of the ED visit
  • Educate patients/families:
    • Return immediately for any fever (even low-grade if neutropenic)
    • Avoid contact sports and high-impact activities (head trauma risk with thrombocytopenia)
    • Avoid NSAIDs
    • Wear medical identification

See Also

External Links

References

  1. ↑ 1.0 1.1 1.2 1.3 1.4 Fanconi Anemia. StatPearls. 2024. PMID: 32119428
  2. ↑ 2.0 2.1 2.2 2.3 2.4 Fanconi Anemia. GeneReviews. NCBI. 2026.
  3. ↑ 3.0 3.1 3.2 Fanconi Anemia. Medscape. 2024.
  4. ↑ 4.0 4.1 4.2 4.3 Fanconi Anemia: Guidelines for Diagnosis and Management. 4th ed. Fanconi Anemia Research Fund.
  5. ↑ 5.0 5.1 Anesthetic Management of a Patient With Fanconi Anemia. Anesth Prog. 2019;66(4):214-217. doi:10.2344/anpr-D-18-00057
Retrieved from "https://www.wikem.org/w/index.php?title=Fanconi_anemia&oldid=386209"